Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
- DOI
- 10.1093/cid/ciad034
- Published
- 2023 Jun 8
- Container
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/cid/ciad034,
title = {Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.},
author = {Sowah LA and Smeaton L and Brates I and Bhattacharya D and Linas B and Kreter B and Wagner-Cardoso S and Solomon S and Sulkowski M and Robbins GK},
year = {2023},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
doi = {10.1093/cid/ciad034},
url = {https://doi.org/10.1093/cid/ciad034}
}RIS
TY - JOUR TI - Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment. AU - Sowah LA AU - Smeaton L AU - Brates I AU - Bhattacharya D AU - Linas B AU - Kreter B AU - Wagner-Cardoso S AU - Solomon S AU - Sulkowski M AU - Robbins GK PY - 2023 JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America DO - 10.1093/cid/ciad034 UR - https://doi.org/10.1093/cid/ciad034 ER -
APA
LA, S., L, S., I, B., D, B., B, L., B, K., S, W., S, S., M, S., & GK, R. (2023). Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciad034
Source records
- pubmed · retrieved 2026-09-26T20:46:21.437Z